What Basophil Testing Tells Us About CSU Patients – Results of the CORSA Study

Basophil testing is the most effective single approach for diagnosing type-IIb autoimmune chronic spontaneous urticaria (TIIbaiCSU). A positive basophil test has been linked to long disease duration, higher disease activity, a poor response to antihistamines and omalizumab, and a better response to...

Full description

Bibliographic Details
Main Authors: João Marcelino, Katrine Baumann, Per Stahl Skov, Maria Conceição Pereira Santos, Inga Wyroslak, Jörg Scheffel, Sabine Altrichter, Anders Woetmann, Manuel Pereira-Barbosa, Célia Costa, Marcus Maurer
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.742470/full
id doaj-06932d6aa806414591e049055aa47dd5
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author João Marcelino
Katrine Baumann
Katrine Baumann
Katrine Baumann
Per Stahl Skov
Per Stahl Skov
Maria Conceição Pereira Santos
Inga Wyroslak
Jörg Scheffel
Jörg Scheffel
Sabine Altrichter
Sabine Altrichter
Anders Woetmann
Anders Woetmann
Manuel Pereira-Barbosa
Célia Costa
Marcus Maurer
Marcus Maurer
spellingShingle João Marcelino
Katrine Baumann
Katrine Baumann
Katrine Baumann
Per Stahl Skov
Per Stahl Skov
Maria Conceição Pereira Santos
Inga Wyroslak
Jörg Scheffel
Jörg Scheffel
Sabine Altrichter
Sabine Altrichter
Anders Woetmann
Anders Woetmann
Manuel Pereira-Barbosa
Célia Costa
Marcus Maurer
Marcus Maurer
What Basophil Testing Tells Us About CSU Patients – Results of the CORSA Study
Frontiers in Immunology
angioedema
autologous serum skin test (ASST)
basophil activation test (BAT)
basophil histamine release test
chronic spontaneous urticaria (CSU)
anti-thyroperoxidase (anti-TPO)
author_facet João Marcelino
Katrine Baumann
Katrine Baumann
Katrine Baumann
Per Stahl Skov
Per Stahl Skov
Maria Conceição Pereira Santos
Inga Wyroslak
Jörg Scheffel
Jörg Scheffel
Sabine Altrichter
Sabine Altrichter
Anders Woetmann
Anders Woetmann
Manuel Pereira-Barbosa
Célia Costa
Marcus Maurer
Marcus Maurer
author_sort João Marcelino
title What Basophil Testing Tells Us About CSU Patients – Results of the CORSA Study
title_short What Basophil Testing Tells Us About CSU Patients – Results of the CORSA Study
title_full What Basophil Testing Tells Us About CSU Patients – Results of the CORSA Study
title_fullStr What Basophil Testing Tells Us About CSU Patients – Results of the CORSA Study
title_full_unstemmed What Basophil Testing Tells Us About CSU Patients – Results of the CORSA Study
title_sort what basophil testing tells us about csu patients – results of the corsa study
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2021-09-01
description Basophil testing is the most effective single approach for diagnosing type-IIb autoimmune chronic spontaneous urticaria (TIIbaiCSU). A positive basophil test has been linked to long disease duration, higher disease activity, a poor response to antihistamines and omalizumab, and a better response to cyclosporine and fenebrutinib. As of now it is unclear what other features are connected to a positive basophil test in chronic spontaneous urticaria (CSU). We aimed to identify features of basophil test-positive CSU patients. We performed a cross-sectional study of 85 CSU patients. Basophil testing was done with the basophil activation test (BAT) and the basophil histamine release assay (BHRA). Data were analysed using SPSS: Student’s t-test, Chi-square test, Odds Ratio, Spearman’s correlation test. Of 85 CSU patients, 44% and 28% tested positive with the BAT and BHRA, respectively. These patients showed higher disease activity and impact, lower levels of disease control and total serum IgE, as well as higher rates of having a positive autologous serum skin test (ASST), angioedema, nocturnal symptoms, symptoms for >5 days/week, and thyroid autoantibodies. The ASST, by itself, was not a good predictor of basophil test results, but it predicted a positive basophil test in up to 100% of cases when combined with angioedema, thyroid autoantibodies or low IgE. In conclusion, a positive basophil test is linked to known features of TIIbaiCSU and novel characteristics including nocturnal symptoms. Further studies on basophil test-positive and -negative CSU patients can help to better understand CSU endotypes and to develop better management approaches.
topic angioedema
autologous serum skin test (ASST)
basophil activation test (BAT)
basophil histamine release test
chronic spontaneous urticaria (CSU)
anti-thyroperoxidase (anti-TPO)
url https://www.frontiersin.org/articles/10.3389/fimmu.2021.742470/full
work_keys_str_mv AT joaomarcelino whatbasophiltestingtellsusaboutcsupatientsresultsofthecorsastudy
AT katrinebaumann whatbasophiltestingtellsusaboutcsupatientsresultsofthecorsastudy
AT katrinebaumann whatbasophiltestingtellsusaboutcsupatientsresultsofthecorsastudy
AT katrinebaumann whatbasophiltestingtellsusaboutcsupatientsresultsofthecorsastudy
AT perstahlskov whatbasophiltestingtellsusaboutcsupatientsresultsofthecorsastudy
AT perstahlskov whatbasophiltestingtellsusaboutcsupatientsresultsofthecorsastudy
AT mariaconceicaopereirasantos whatbasophiltestingtellsusaboutcsupatientsresultsofthecorsastudy
AT ingawyroslak whatbasophiltestingtellsusaboutcsupatientsresultsofthecorsastudy
AT jorgscheffel whatbasophiltestingtellsusaboutcsupatientsresultsofthecorsastudy
AT jorgscheffel whatbasophiltestingtellsusaboutcsupatientsresultsofthecorsastudy
AT sabinealtrichter whatbasophiltestingtellsusaboutcsupatientsresultsofthecorsastudy
AT sabinealtrichter whatbasophiltestingtellsusaboutcsupatientsresultsofthecorsastudy
AT anderswoetmann whatbasophiltestingtellsusaboutcsupatientsresultsofthecorsastudy
AT anderswoetmann whatbasophiltestingtellsusaboutcsupatientsresultsofthecorsastudy
AT manuelpereirabarbosa whatbasophiltestingtellsusaboutcsupatientsresultsofthecorsastudy
AT celiacosta whatbasophiltestingtellsusaboutcsupatientsresultsofthecorsastudy
AT marcusmaurer whatbasophiltestingtellsusaboutcsupatientsresultsofthecorsastudy
AT marcusmaurer whatbasophiltestingtellsusaboutcsupatientsresultsofthecorsastudy
_version_ 1716865918083006464
spelling doaj-06932d6aa806414591e049055aa47dd52021-09-28T13:54:23ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-09-011210.3389/fimmu.2021.742470742470What Basophil Testing Tells Us About CSU Patients – Results of the CORSA StudyJoão Marcelino0Katrine Baumann1Katrine Baumann2Katrine Baumann3Per Stahl Skov4Per Stahl Skov5Maria Conceição Pereira Santos6Inga Wyroslak7Jörg Scheffel8Jörg Scheffel9Sabine Altrichter10Sabine Altrichter11Anders Woetmann12Anders Woetmann13Manuel Pereira-Barbosa14Célia Costa15Marcus Maurer16Marcus Maurer17Immunoallergology Department, Hospital Santa Maria, Centro Hospitalar Universitário Lisboa Norte E.P.E., Lisbon, PortugalDermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Berlin, GermanyFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, GermanyContract Research Dprt., RefLab ApS, Copenhagen, DenmarkContract Research Dprt., RefLab ApS, Copenhagen, DenmarkOdense Research Center for Anaphylaxis (ORCA), Urticaria Center of Reference and Excellence (UCARE), Odense University Hospital, Odense, DenmarkLaboratory of Clinical Immunology, Faculdade de Medicina, Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, PortugalDermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Berlin, GermanyDermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Berlin, GermanyFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, GermanyDermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Berlin, GermanyFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, GermanyDermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Berlin, GermanyFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, GermanyImmunoallergology Department, Hospital Santa Maria, Centro Hospitalar Universitário Lisboa Norte E.P.E., Lisbon, PortugalImmunoallergology Department, Hospital Santa Maria, Centro Hospitalar Universitário Lisboa Norte E.P.E., Lisbon, PortugalDermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Berlin, GermanyFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, GermanyBasophil testing is the most effective single approach for diagnosing type-IIb autoimmune chronic spontaneous urticaria (TIIbaiCSU). A positive basophil test has been linked to long disease duration, higher disease activity, a poor response to antihistamines and omalizumab, and a better response to cyclosporine and fenebrutinib. As of now it is unclear what other features are connected to a positive basophil test in chronic spontaneous urticaria (CSU). We aimed to identify features of basophil test-positive CSU patients. We performed a cross-sectional study of 85 CSU patients. Basophil testing was done with the basophil activation test (BAT) and the basophil histamine release assay (BHRA). Data were analysed using SPSS: Student’s t-test, Chi-square test, Odds Ratio, Spearman’s correlation test. Of 85 CSU patients, 44% and 28% tested positive with the BAT and BHRA, respectively. These patients showed higher disease activity and impact, lower levels of disease control and total serum IgE, as well as higher rates of having a positive autologous serum skin test (ASST), angioedema, nocturnal symptoms, symptoms for >5 days/week, and thyroid autoantibodies. The ASST, by itself, was not a good predictor of basophil test results, but it predicted a positive basophil test in up to 100% of cases when combined with angioedema, thyroid autoantibodies or low IgE. In conclusion, a positive basophil test is linked to known features of TIIbaiCSU and novel characteristics including nocturnal symptoms. Further studies on basophil test-positive and -negative CSU patients can help to better understand CSU endotypes and to develop better management approaches.https://www.frontiersin.org/articles/10.3389/fimmu.2021.742470/fullangioedemaautologous serum skin test (ASST)basophil activation test (BAT)basophil histamine release testchronic spontaneous urticaria (CSU)anti-thyroperoxidase (anti-TPO)